News2 mins ago
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
– ATG-031, discovered and developed in-house by Antengene, is the world’s first anti-CD24 antibody to advance to the clinic in oncology and Antengene’s third drug candidate...
